摘要
目的 研究ＣＹＦＲＡ２１１ 作为血清肿瘤标记物对非小细胞肺癌诊断及病情、疗效判断的临床应用价值。方法 分别于术前、术后２ 周、术后１５ ～１８ 个月采集非小细胞肺癌患者血清样本共１２６ 份，用放射免疫分析法检测其ＣＹＦＲＡ２１１ 含量。结果 初治的非小细胞肺癌患者ＣＹＦＲＡ２１１ 总阳性率为４９３％ ，其中鳞癌６９２％ ，腺癌２５０％ 。鳞癌患者的血清ＣＹＦＲＡ２１１ 含量显著高于腺癌（ Ｐ＜００００１） 。血清ＣＹＦＲＡ２１１ 含量与临床ＴＮＭ 分期显著相关（ Ｐ＝ ００００１），随期别增加而升高。ＣＹＦＲＡ２１１ 含量在术后２ 周显著下降（ Ｐ＝ ００００５） 。术后２ 周与术后１５ ～１８ 个月的血清样本中ＣＹＦＲＡ２１１ 含量比较：病情稳定者，ＣＹＦＲＡ２１１ 含量无明显升高（ Ｐ＝ ０６２３３） ；病情进展者，ＣＹＦＲＡ２１１含量明显升高（ Ｐ＝０００５１） 。结论 ＣＹＦＲＡ２１１ 检测对非小细胞肺癌患者的诊断。
Objective To evaluate the clinical usefulness of CYFRA21 1 as a serum tumor marker in diagnosis, evaluation of clinical status and prognosis of patients with non small cell lung cancer (NSCLC). Methods CYFRA21 1 in 126 serum samples of NSCLC patients was measured by radioimmunoassay. Of the 126 samples, 71 were collected before treatment, 29 at two weeks after operation, and 26 after 15～18 months follow up.Results CYFRA21 1 was positive in 49.3% of the NSCLC patients who had not received any treatment. The positive rate was 69.2% for squamous cell carcinoma, and 25.0% for adenocarcinoma. The serum level of CYFRA21 1 was significantly higher in squamous cell carcinoma than in adenocarcinoma ( P < 0.0001). The serum level of CYFRA21 1 well correlated and increased with TNM staging ( P =0.0001). The level decreased significantly within two weeks after surgical operation in 29 cases ( P =0.0005). On follow up for 15～18 months, no change in CYFRA21 1 level was obseved in 16 patients whose disease was stable, while there was significant increase in 10 patients with progressive disease. Conclusion CYFRA21 1 is a soluble fragment of cytokeratin 19 in serum of patients with NSCLC. It can be used as a useful tumor marker of NSCLC.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
1999年第4期287-289,共3页
Chinese Journal of Oncology
